BridgeMD
New treatment option for Coronary Angiography
Official title Timing of Anticoagulant Administration During Radial Access Percutaneous Coronary Intervention: the HERA-PCI Study (Heparin Early for Radial Access Percutaneous Coronary Intervention)
ClinicalTrials.gov ID: NCT06890312
What this study is testing
- What it's testing
- While the reduced hemorrhagic risk of radial access for percutaneous coronary intervention compared to femoral access is well-established, its main complication remains radial artery occlusion, which can occur in up to 30% of patients. Anticoagulation is the primary preventive measure recommended in clinical practice to reduce the risk of this complication, typically involving heparin injection during the procedure in most centers.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patients having 18 years old or older, regardless of gender, undergoing percutaneous radial coronary intervention
- Subject affiliated to a social protection health insurance
- Subject able to understand the objectives and risks of the research and to provide dated and signed consent
- Subject who has been informed of the results of the preliminary medical examination
You likely can't join if
- Contraindication to the use of heparin (history of heparin-induced thrombocytopenia)
- Very high bleeding risk defined by recent bleeding (\<6 months) of type 3 of the BARC classification
- Subject in an exclusion period (determined by a previous or ongoing study)
- Inability to give the subject enlightened information (subject in an emergency situation, difficulties in understanding the subject, etc.)
- Subject under safeguard of justice
- Subject under guardianship or curatorship
See the full eligibility criteria
- Patients having 18 years old or older, regardless of gender, undergoing percutaneous radial coronary intervention
- Subject affiliated to a social protection health insurance
- Subject able to understand the objectives and risks of the research and to provide dated and signed consent
- Subject who has been informed of the results of the preliminary medical examination
- Contraindication to the use of heparin (history of heparin-induced thrombocytopenia)
- Very high bleeding risk defined by recent bleeding (\<6 months) of type 3 of the BARC classification
- Subject in an exclusion period (determined by a previous or ongoing study)
- Inability to give the subject enlightened information (subject in an emergency situation, difficulties in understanding the subject, etc.)
- Subject under safeguard of justice
- Subject under guardianship or curatorship
- Pregnancy
- Breastfeeding
- Patient on anticoagulant treatment: anti-vitamin K, direct oral anticoagulants (DOACs).
The study team makes the final eligibility decision.
Where it's taking place
- Strasbourg, Bas-Rhin, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Strasbourg, Bas-Rhin, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.